Table_1_Combination therapy with 3% diquafosol tetrasodium ophthalmic solution and sodium hyaluronate: an effective therapy for patients with dry eye after femtosecond laser-assisted in situ keratomileusis.docx

PurposeTo assess the effect of combination therapy with 3% diquafosol tetrasodium (DQS) and sodium hyaluronate (HA) for dry eye after femtosecond laser-assisted in situ keratomileusis (FS-LASIK).DesignProspective nonrandomized comparative trial.MethodsThe prospective study included 80 eyes of 40 patients who underwent FS-LASIK with or without preoperative dry eye. Patients were divided into a combination group and a HA group according to their willingness and the doctor’s advice. The combination group was treated with DQS six times a day and HA four times a day, and the HA group was treated with HA four times a day after FS-LASIK. Ocular surface disease index (OSDI), ocular symptom score, vision-related score, environmental score, tear meniscus height (TMH), first non-invasive tear breakup time (NIBUT-First), average non-invasive tear breakup time (NIBUT-Ave), tear breakup time (TBUT), Schirmer I test (SIT), corneal fluorescein staining score (CFS), bulbar redness score, limbal redness score, lipid layer grade (LLG), meiboscore, lid margin abnormality, corneal sensitivity, and corneal nerve parameters were examined before surgery and at 1 week and 1 month after surgery. Surface regularity index (SRI) was also examined before surgery and at 1 month postoperatively.ResultsOSDI score (p = 0.024) and vision-related score (p = 0.026) were significantly lower in the combination group than in the HA group at 1 month after FS-LASIK, especially in patients with preoperative dry eye symptoms. The increasements of CFS (p = 0.018), bulbar redness score (p = 0.021), and limbal redness score (p = 0.009) were significantly lower in the combination group than in the HA group at 1 week after FS-LASIK. But other ocular surface parameters showed no difference between both groups at 1 week and 1 month after FS-LASIK. LLG was significantly higher in the combination group than in the HA group at 1 week (p = 0.004) and 1 month (p ConclusionThe combination therapy with DQS and HA significantly relieved subjective symptoms, improved ocular surface status, and had the potential to promote corneal nerve growth in patients after FS-LASIK.</p

Additional file 1 of Acute effects of resistance-type and cycling-type high-intensity interval training on arterial stiffness, cardiac autonomic modulation and cardiac biomarkers

Additional file 1

Expression of genes encoding LPL and lipoprotein receptors in the liver of large yellow croaker.

<p>Values (means±S.E.M.) in bars that have the same letter are not significantly different (<i>P</i>>0.05; Tukey’s) among treatments (n = 3). LPL: lipoprotein lipase; LRP-1: LDL receptor-related protein-1; SRBI: scavenger receptor class BI.</p

Effects of dietary lipid levels on the moisture and lipid contents of the whole body, liver and muscle of large yellow croaker (<i>Larimichthys crocea</i>) (%, wet weight)^*.

<p>*Values (means±S.E.M.) that share the same letter in the same row are not significantly different (<i>P</i><0.05; Tukey’s test) among treatments (n = 3).</p><p>Effects of dietary lipid levels on the moisture and lipid contents of the whole body, liver and muscle of large yellow croaker (<i>Larimichthys crocea</i>) (%, wet weight)^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129937#t005fn001" target="_blank">*</a>}.</p

Effects of dietary lipid levels on the growth performance, somatic parameters and plasma biochemical indexes of large yellow croaker (<i>Larimichthys crocea</i>)^*.

<p>*Values (means±S.E.M.) that share the same letter in the same row are not significantly different (<i>P</i><0.05; Tukey’s test) among treatments (n = 3).</p><p>¹Survival rate (%) = 100×final fish number/initial fish number.</p><p>²Specific growth rate (%day^-1) = 100×[ln (final weight)-ln (initial weight)]/days.</p><p>³Feed intake (day^-1) = feed consumption (g)/(days×(final body weight + initial body weight)/2).</p><p>⁴Feed conversion ratio = feed consumption (g)/wet weight gain (g).</p><p>⁵Hepato-somatic index = 100×(liver weight/body weight).</p><p>⁶Viscera-somatic index = 100×(viscera weight/body weight).</p><p>⁷NEFA: non-esterified fatty acids.</p><p>Effects of dietary lipid levels on the growth performance, somatic parameters and plasma biochemical indexes of large yellow croaker (<i>Larimichthys crocea</i>)^{<a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0129937#t004fn001" target="_blank">*</a>}.</p

Fatty acid composition of the experimental diets (for total fatty acids).

<p>¹nd: not detected.</p><p>²SFA: saturated fatty acids.</p><p>³MUFA: monounsaturated fatty acids.</p><p>⁴PUFA: polyunsaturated fatty acids.</p><p>⁵LC-PUFA: long-chain-polyunsaturated fatty acids.</p><p>Fatty acid composition of the experimental diets (for total fatty acids).</p

Primer pair sequences and amplicon size of the genes used for real-time PCR.

<p>apo: apolipoprotein; MTP: microsomal TAG transfer protein; LPL: lipoprotein lipase; LDLR: low-density lipoprotein receptor; LRP-1: lipoprotein receptor-related protein-1; SRBI: scavenger receptor class BI; CD36: cluster of differentiation 36; FATP1: fatty acid transport protein 1; FABP: fatty acid binding protein; FAS: fatty acid synthase; DGAT2: acyl-CoA: diacylglycerol acyltransferase 2; ATGL: adipose triglyceride lipase; CPT I: carnitine palmitoyltransferase I; ACO: acyl-CoA oxidase.</p><p>Primer pair sequences and amplicon size of the genes used for real-time PCR.</p

Expression of genes related to VLDL assembly in the liver of large yellow croaker.

<p>Values (means±S.E.M.) in bars that have the same letter are not significantly different (<i>P</i>>0.05; Tukey’s test) among treatments (n = 3). apo: apolipoprotein; MTP: microsomal triacylglycerol transfer protein.</p

Formulation and proximate composition of the experimental diets.

<p>¹All of these ingredients were supplied by Great Seven Biotechnology Co., Ltd., China.</p><p>²Vitamin premix (mg or g/kg diet): cholecalciferol, 5 mg; retinol acetate, 32 mg; thiamin 25 mg;vitamin B₁₂ (1%), 10 mg; riboflavin, 45 mg; pyridoxine HCl, 20 mg; ascorbic acid, 2000 mg; alpha-tocopherol (50%), 240 mg; vitamin K₃, 10 mg; pantothenic acid, 60 mg; inositol, 800 mg; niacin acid, 200 mg; folic acid, 20 mg; biotin (2%), 60 mg; choline chloride (50%), 4000 mg;microcrystalline cellulose, 12.47 g.</p><p>³Mineral premix (mg or g/kg diet): CuSO₄·5H₂O, 10 mg; Ca (IO₃)₂·6H₂O (1%), 60 mg; CoCl₂·6H₂O (1%), 50 mg; FeSO₄·H₂O, 80 mg; MgSO₄·7H₂O, 1200 mg; MnSO₄·H₂O, 45 mg; NaSeSO₃·5H₂O (1%), 20 mg; ZnSO₄·H₂O, 50 mg; CaH₂PO₄·H₂O, 10 g; zeolite, 8.485 g.</p><p>⁴Attractants: glycine and betaine.</p><p>⁵Mold inhibitor: contained 50% calcium propionic acid and 50% fumaric acid.</p><p>Formulation and proximate composition of the experimental diets.</p

Expression of genes related totriacylglycerol synthesis and catabolism in the liver of large yellow croaker.

<p>Values (means±S.E.M.) in bars that have the same letter are not significantly different (<i>P</i>>0.05; T test for FAS, DGAT2 and CPT I in the liver, and Tukey’s test for the other genes) among treatments (n = 3). FAS: fatty acid synthase; DGAT2: acyl-CoA:diacylglycerol acyltransferase 2; ATGL: adipose triglyceride lipase; CPT I: carnitine palmitoyltransferase I; ACO: acyl-CoA oxidase.</p